Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Actavis | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Actavis

North American Brands business up 188% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Actavis

4Q Revenues: $4.1 billion (+46%)

4Q Loss: $732.9 million (loss of $148.4 million 4Q13)

FY Revenues: $13.1 billion (+51%)

FY Loss: $1.6 billion (loss of $750.4 million FY13)

Comments: North American Brands business revenues were $1.8 billion, up 188%, primarily driven by the acquisition of Forest, as well as double-digit growth for the Namenda franchise, Linzess, Estrace Cream, Teflaro, and Bystolic. North American Generics & International revenue was $1.8 billion, up 1%, with growth of generic versions of Lidoderm and Concerta, and 4Q launches of generic versions of Intuniv and Celebrex, offset by a decline of $80 million associated with the divested Western European assets in April 2014. Following the close of the merger with Allergan, the company will change its name to Allergan.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters